228 related articles for article (PubMed ID: 16164632)
21. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
22. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.
Doublier S; Salvidio G; Lupia E; Ruotsalainen V; Verzola D; Deferrari G; Camussi G
Diabetes; 2003 Apr; 52(4):1023-30. PubMed ID: 12663475
[TBL] [Abstract][Full Text] [Related]
23. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis.
Wang Y; Heilig K; Saunders T; Minto A; Deb DK; Chang A; Brosius F; Monteiro C; Heilig CW
Am J Physiol Renal Physiol; 2010 Jul; 299(1):F99-F111. PubMed ID: 20375117
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiological role of Amadori-glycated proteins in diabetic microangiopathy.
Schalkwijk CG; Lieuw-a-Fa M; van Hinsbergh VW; Stehouwer CD
Semin Vasc Med; 2002 May; 2(2):191-7. PubMed ID: 16222610
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-21 in glomerular injury.
Lai JY; Luo J; O'Connor C; Jing X; Nair V; Ju W; Randolph A; Ben-Dov IZ; Matar RN; Briskin D; Zavadil J; Nelson RG; Tuschl T; Brosius FC; Kretzler M; Bitzer M
J Am Soc Nephrol; 2015 Apr; 26(4):805-16. PubMed ID: 25145934
[TBL] [Abstract][Full Text] [Related]
26. Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells.
Cohen MP; Ziyadeh FN; Lautenslager GT; Cohen JA; Shearman CW
Am J Physiol; 1999 May; 276(5):F684-90. PubMed ID: 10330050
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation.
Cohen MP; Hud E; Wu VY; Shearman CW
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):5089-93. PubMed ID: 18599566
[TBL] [Abstract][Full Text] [Related]
28. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy.
Wang SN; LaPage J; Hirschberg R
Kidney Int; 2000 Mar; 57(3):1002-14. PubMed ID: 10720953
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
Wang S; Li Y; Zhao J; Zhang J; Huang Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
[TBL] [Abstract][Full Text] [Related]
30. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy.
Wolf G; Chen S; Ziyadeh FN
Diabetes; 2005 Jun; 54(6):1626-34. PubMed ID: 15919782
[TBL] [Abstract][Full Text] [Related]
31. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Sung SH; Ziyadeh FN; Wang A; Pyagay PE; Kanwar YS; Chen S
J Am Soc Nephrol; 2006 Nov; 17(11):3093-104. PubMed ID: 16988063
[TBL] [Abstract][Full Text] [Related]
32. Early, but not advanced, glomerulopathy is reversed by pancreatic islet transplants in experimental diabetic rats: correlation with glomerular extracellular matrix mRNA levels.
Pugliese G; Pricci F; Pesce C; Romeo G; Lenti E; Caltabiano V; Vetri M; Purrello F; Di Mario U
Diabetes; 1997 Jul; 46(7):1198-206. PubMed ID: 9200656
[TBL] [Abstract][Full Text] [Related]
33. Accumulation of glycated albumin in end-stage renal failure: evidence for the principle of "physiological microalbuminuria".
Donnelly SM
Am J Kidney Dis; 1996 Jul; 28(1):62-6. PubMed ID: 8712223
[TBL] [Abstract][Full Text] [Related]
34. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Zhou G; Cheung AK; Liu X; Huang Y
Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
[TBL] [Abstract][Full Text] [Related]
35. Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF.
Wang Y; Heilig KO; Minto AW; Chen S; Xiang M; Dean DA; Geiger RC; Chang A; Pravtcheva DD; Schlimme M; Deb DK; Wang Y; Heilig CW
Lab Invest; 2010 Jan; 90(1):83-97. PubMed ID: 19918242
[TBL] [Abstract][Full Text] [Related]
36. Prevention of decline in renal function in the diabetic db/db mouse.
Cohen MP; Clements RS; Cohen JA; Shearman CW
Diabetologia; 1996 Mar; 39(3):270-4. PubMed ID: 8721771
[TBL] [Abstract][Full Text] [Related]
37. Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy.
Luo P; Zhou Y; Chang HH; Zhang J; Seki T; Wang CY; Inscho EW; Wang MH
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F556-63. PubMed ID: 19129258
[TBL] [Abstract][Full Text] [Related]
38. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo.
Menne J; Meier M; Park JK; Boehne M; Kirsch T; Lindschau C; Ociepka R; Leitges M; Rinta-Valkama J; Holthofer H; Haller H
Kidney Int; 2006 Oct; 70(8):1456-62. PubMed ID: 16955103
[TBL] [Abstract][Full Text] [Related]
39. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells.
Kim SI; Han DC; Lee HB
J Am Soc Nephrol; 2000 Jan; 11(1):80-87. PubMed ID: 10616843
[TBL] [Abstract][Full Text] [Related]
40. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
